Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CVS stock price vs NVDA: inconclusive — current versus $52.91 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NVDA's multiple
Implied fair value · at CVS's multiple
Needs CVS P/E.
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
17 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 100% equity / 0% debt · EV / Revenue 20.80x · EV proxy / EBITDA proxy 33.72x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CVS HEALTH Corp · implied price per share
Bear
$43.35
Base
$58.49
Bull
$78.21
NVIDIA CORP · implied price per share
Bear
$43.09
Base
$52.57
Bull
$59.95
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Walgreens Boots Alliance, Inc.
CVS vs WBA
UNITEDHEALTH GROUP INC
CVS vs UNH
Walmart Inc.
CVS vs WMT
Cigna Group
CVS vs CI
HUMANA INC
CVS vs HUM
Elevance Health, Inc.
CVS vs ELV
ADVANCED MICRO DEVICES INC
CVS vs AMD
INTEL CORP
CVS vs INTC
TEXAS INSTRUMENTS INC
CVS vs TXN
Broadcom Inc.
CVS vs AVGO
QUALCOMM INC/DE
CVS vs QCOM
MICROCHIP TECHNOLOGY INC
CVS vs MCHP
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CVS can materially improve margins and reduce leverage, then hold or accumulate on weakness because the current price already embeds a steep earnings-multiple penalty; otherwise, avoid the stock because the operating profile is far weaker than NVDA and the model implies substantial downside.
CVS trades at a much lower P/S and EV/Revenue than NVDA, but its implied price from the P/E framework is still 47.3% below the current price, highlighting that the market is not granting CVS a high earnings multiple relative to the comparison set. The gap is driven more by CVS's low profitability and slow growth than by simple multiple compression.
Supporting Metrics
